Company intelligence / Profile preview
Skyline Therapeutics
Shanghai, Shanghai, Chinaskytx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Skyline Therapeutics has multiple programs in development, with SKG-0106 for wet age-related macular degeneration in Phase 1 clinical trials, and SKG-0702 and SKG-0701 for Hepatolenticular Degeneration in preclinical stage.
- Therapeutic areas
- Metabolic DisordersRare DiseasesHematologyCardiovascularOphthalmologyNeurology
- Modalities
- AAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
BioMarin Pharmaceutical Inc.
Beyond the preview
Go deeper on Skyline Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skyline Therapeutics.